Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

CVN058 shows promise in Phase Ib schizophrenia cognition study

europeanpharmaceuticalreviewNovember 20, 2020

Tag: CVN058 , schizophrenia , Cerevance

PharmaSources Customer Service